| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.2 | 7e-10 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-09 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.19 | 8e-09 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-08 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.27 | 2e-08 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-08 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-07 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.25 | 8e-07 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-06 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |